Metastatic

HER2

HER2 +

BRS0070
Phase 1B
PF-05082566 in Combo w/ Adotristuzumab, Emtansine or Trastuzumab in HER2+ Breast Cancer
PI: Sledge Stanford

HER2 -

Pre and Post Menopausal

Germline or Somatic Mutation

Hergulin (+)

≤ 3 lines of prior cytotoxic chemo in part 1;
≤ 1 line of prior cytotoxic chemo in part 2

ER +/- PR+,

≥ 3 lines of prior cytotoxic chemo in part 1;
≥ 1 line of prior cytotoxic chemo in part 2

DNA Damage and Repair (DDR) (+)

BRS0087
Phase III Capecitabine +/- Tesetaxel vs in HER2- /Hormone Receptor+/Local Advd /Metastatic Brst Can
PI: Pegram Pending

BRS0050
Phase II BMN 573 in BRCA1 + BRCA2 Wild-Type Patients w/ Advanced Triple-Neg / HER2-Neg Breast Cancer
PI: Telli Stanford

BRS0080
Phase II Seribantumab + Fulvestrant in Hormone Receptor+ HER2- Metastatic Breast Cancer
PI: Massanweh Merrimack Pharmaceuticals

BRS0089
Phase I G1T48 in Women w/ Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer
PI: Pegram Pending

VAR0166
Phase Ib/II Avelumab In Combination with Talazoparib In Locally Advanced or Metastatic Solid Tumors
Cohort B
PI: Telli Pending

KEY

Pending

Open for Enrollment

Observational Study

Optional Path

Link

Trial Posting

Extension Study

Immunotherapy

Enrollment on Hold